Canakinumab for atherosclerosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Apr 2011: Trial registered, NCT01327846
  2. 11 Apr 2011: Trial started, NCT01327846

The trials

NCT01327846: Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

State
Completed
Phase
Phase 3
People
10,066 taking part
Started
11 Apr 2011
Primary completion
28 Mar 2017
Arms
Canakinumab Dose 50 mg, Canakinumab Dose 150 mg, Canakinumab Dose 300 mg
Results
Posted on the registry
  1. 4 Apr 2011: Trial registered
  2. 11 Apr 2011: Trial started
  3. 14 Apr 2019: Trial completed
  4. 22 Jan 2020: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Ilaris.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.